MicroRNA-181 family predicts response to concomitant
chemoradiotherapy with temozolomide in glioblastoma patients

J 2010

MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients

SLABÝ, Ondřej; Roman LAKOMÝ; Pavel FADRUS; Roman HRSTKA; Leoš KŘEN et al.

Základní údaje

Originální název

MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients

Autoři

Vydání

Neoplasma, Bratislava, Slovakia, Slovak Academy of Sciences, 2010, 0028-2685

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10600 1.6 Biological sciences

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.449

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/10:00051702

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.4149/neo_2010_03_264

UT WoS

000277412800012

Klíčová slova anglicky

microRNA; MGMT methylation; glioblastoma; chemoradiotherapy; temozolomide

Příznaky

Mezinárodní význam

Změněno: 20. 4. 2012 15:05, Mgr. Michal Petr

Anotace

V originále

MicroRNAs are endogenously expressed regulatory noncoding RNAs. Previous studies showed altered expression levels of several microRNAs in glioblastomas. In this study, we examined the expression levels of selected microRNAs in 22 primary glioblastomas and six specimens of adult brain tissue by real-time PCR method. In addition, we examined methylation status of MGMT promoter by methylation-specific real-time PCR, as this has been shown to be a predictive marker in glioblastomas. MGMT methylation status was not correlated with response to concomitant chemoradiotherapy with temozolomide (RT/TMZ). MiR-221 (p=0,016), miR-222 (p=0,038), miR-181b (p=0,036), miR-181c (p=0,043) and miR-128a (p=0,001) were significantly down-regulated in glioblastomas. The most significant change was observed for up-regulation in miR-21 expression in glioblastomas (p<0,001). MiR-181b and miR-181c were significantly down-regulated in patients who responded to RT/TMZ (p=0,016; p=0,047, respectively) in comparison to patients with progredient disease. Our data indicate for the first time that expression levels of miR-181b and miR-181c could serve as a predictive marker of response to RT/TMZ therapy in glioblastoma patients.

Citovat

SLABÝ, Ondřej; Roman LAKOMÝ; Pavel FADRUS; Roman HRSTKA; Leoš KŘEN; Eva LŽIČAŘOVÁ; Martin SMRČKA; Marek SVOBODA; H. DOLEŽALOVÁ; Jana NOVÁKOVÁ; Dalibor VALÍK; Rostislav VYZULA a Jaroslav MICHÁLEK. MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients. Neoplasma. Bratislava, Slovakia: Slovak Academy of Sciences, 2010, roč. 57, č. 3, s. 264-269. ISSN 0028-2685. Dostupné z: https://doi.org/10.4149/neo_2010_03_264.

@article{919656,
   author = {Slabý, Ondřej and Lakomý, Roman and Fadrus, Pavel and Hrstka, Roman and Křen, Leoš and Lžičařová, Eva and Smrčka, Martin and Svoboda, Marek and Doležalová, H. and Nováková, Jana and Valík, Dalibor and Vyzula, Rostislav and Michálek, Jaroslav},
   article_location = {Bratislava, Slovakia},
   article_number = {3},
   doi = {https://doi.org/10.4149/neo_2010_03_264},
   keywords = {microRNA; MGMT methylation; glioblastoma; chemoradiotherapy; temozolomide},
   language = {eng},
   issn = {0028-2685},
   journal = {Neoplasma},
   title = {MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients},
   volume = {57},
   year = {2010}
}

TY  - JOUR
ID  - 919656
AU  - Slabý, Ondřej - Lakomý, Roman - Fadrus, Pavel - Hrstka, Roman - Křen, Leoš - Lžičařová, Eva - Smrčka, Martin - Svoboda, Marek - Doležalová, H. - Nováková, Jana - Valík, Dalibor - Vyzula, Rostislav - Michálek, Jaroslav
PY  - 2010
TI  - MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients
JF  - Neoplasma
VL  - 57
IS  - 3
SP  - 264-269
EP  - 264-269
PB  - Slovak Academy of Sciences
SN  - 00282685
KW  - microRNA
KW  - MGMT methylation
KW  - glioblastoma
KW  - chemoradiotherapy
KW  - temozolomide
N2  - MicroRNAs are endogenously expressed regulatory noncoding RNAs. Previous studies showed altered expression levels of several microRNAs in glioblastomas. In this study, we examined the expression levels of selected microRNAs in 22 primary glioblastomas and six specimens of adult brain tissue by real-time PCR method. In addition, we examined methylation status of MGMT promoter by methylation-specific real-time PCR, as this has been shown to be a predictive marker in glioblastomas. MGMT methylation status was not correlated with response to concomitant chemoradiotherapy with temozolomide (RT/TMZ). MiR-221 (p=0,016), miR-222 (p=0,038), miR-181b (p=0,036), miR-181c (p=0,043) and miR-128a (p=0,001) were significantly down-regulated in glioblastomas. The most significant change was observed for up-regulation in miR-21 expression in glioblastomas (p<0,001). MiR-181b and miR-181c were significantly down-regulated in patients who responded to RT/TMZ (p=0,016; p=0,047, respectively) in comparison to patients with progredient disease. Our data indicate for the first time that expression levels of miR-181b and miR-181c could serve as a predictive marker of response to RT/TMZ therapy in glioblastoma patients.
ER  -

SLABÝ, Ondřej; Roman LAKOMÝ; Pavel FADRUS; Roman HRSTKA; Leoš KŘEN; Eva LŽIČAŘOVÁ; Martin SMRČKA; Marek SVOBODA; H. DOLEŽALOVÁ; Jana NOVÁKOVÁ; Dalibor VALÍK; Rostislav VYZULA a Jaroslav MICHÁLEK. MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients. \textit{Neoplasma}. Bratislava, Slovakia: Slovak Academy of Sciences, 2010, roč.~57, č.~3, s.~264-269. ISSN~0028-2685. Dostupné z: https://doi.org/10.4149/neo\_{}2010\_{}03\_{}264.

Přehled o publikaci